ReviewCurrent oncology reports2016
Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.
Review in Current oncology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and Efficacy Analysis of Targeted and Immune Combination Therapy in Advanced Melanoma-A Systematic Review and Network Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- The Role of Transcriptional and Atypical Cyclin-Dependent Protein Kinases in Melanoma.Cancers · 2026Review
- Receptor tyrosine kinase inhibitor tivozanib regulates cell state plasticity and restores MITF dependency in BRAF wild-type melanoma.Acta pharmacologica Sinica · 2025Article
- Using liquid biopsies to guide treatment and monitor response in BRAF V600E positive adenocarcinoma of unknown primary.BMJ case reports · 2025Article
- Small-Bowel Metastatic Melanoma From Primary Mucosal Melanoma of the Anus: A Comprehensive Case Report.ACG case reports journal · 2025Article
- Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-xInternational journal of molecular sciences · 2024Article
- CSNK1E is involved in TGF-β1 induced epithelial mesenchymal transformationas and related to melanoma immune heterogeneity.Frontiers in pharmacology · 2024Article
- Bcl-2 family inhibitors sensitize human cancer models to therapy.Cell death & disease · 2023Article
- Pre-clinical modeling of cutaneous melanoma.Nature communications · 2020Review
- Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.Journal of experimental & clinical cancer research : CR · 2020Article
- The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb.International journal of molecular sciences · 2019Article
- (Arg)Journal of experimental & clinical cancer research : CR · 2018Article
- Article
- Article
- Identification of recurrent mutational events in anorectal melanoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner.Oncotarget · 2016Article
- Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report.Medicine · 2016Article
- Amelanotic Gastric Metastases From Melanoma Presenting as Gastrointestinal Bleeding Shortly After Diagnosis: A Case Report.Journal of investigative medicine high impact case reportsArticle
- Immunological effects of BRAF+MEK inhibition.OncoimmunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Patients with metastatic melanoma have historically had dismal outcomes. The last several years has seen the emergence of effective immune and targeted therapies for metastatic melanoma. Targeted therapies have primarily impacted the 40-50% of patients with BRAF(V600) mutated melanoma. The remainder of patients with advanced melanoma harbor a wide spectrum of mutations other than BRAF(V600) that are associated with unique pathophysiological, prognostic, and therapeutic implications. The treatment of this subset of patients is a challenging problem. In recent years, preclinical and early clinical studies have suggested that inhibitors of mitogen activated protein kinase (MAPK) pathway and parallel signaling networks may have activity in treatment of BRAF(V600) wild-type (WT) melanoma. In this review, we will discuss available and developing therapies for BRAF WT patients with metastatic melanoma, particularly focusing on molecular targeted options for various genetically defined melanoma subsets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.